$ABBISKO-B (02256.HK)$
On April 1 2025, Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics”) announced that Merck has exercised the global commercialization option for pimicotinib(ABSK021), with an option exercise fee of USD85.0 million, under the licensing agreement signed in December 2023. The development represents further deepening of the collaboration, underscoring the unwavering commitment and confidence tha...

$JW THERAP-B (02126.HK)$ can buy?

$ABBISKO-B (02256.HK)$ perfect bo n instant gain in strong sector  

$JACOBIO-B (01167.HK)$ powerful bo from power play setup

$ABBISKO-B (02256.HK)$ potential bo power play 👀

$ANTENGENE-B (06996.HK)$ still go up tomorrow?

$CANBRIDGE-B (01228.HK)$ why the sudden
increase